Morusin suppresses breast cancer cell growth in vitro and in vivo through C/EBPβ and PPARγ mediated lipoapoptosis

Journal of Experimental and Clinical Cancer Research

Volumn 34, Issue 1, 2015, Pages

  Li, Haiyan ^a   Wang, Qiaoping ^a   Dong, Lihua ^a   Liu, Chuanlan ^a   Sun, Zhen ^a   Gao, Ling ^a   Wang, Xiujie ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Adipogenic differentiation; Apoptosis; Breast cancer; Growth inhibition; Lipoapoptosis; Morusin

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN BETA; FLAVONOID; MORUSIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ADIPOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CELL DIFFERENTIATION; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIPOAPOPTOSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; BREAST NEOPLASMS; CELL CYCLE; CELL PROLIFERATION; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; METABOLISM; PATHOLOGY; TUMOR CELL LINE; TUMOR STEM CELL ASSAY; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CCAAT-ENHANCER-BINDING PROTEIN-BETA; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; FEMALE; FLAVONOIDS; HUMANS; MICE; PPAR GAMMA; TUMOR BURDEN; TUMOR STEM CELL ASSAY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84946203876     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/s13046-015-0252-4     Document Type: Article

References (54)

1. Tao Z, Shi A, Lu C, Song T, Zhang Z, Zhao J. Breast Cancer: Epidemiology and Etiology. Cell Biochem Biophys. 2014. [Epub ahead of print]
2. Confortini CC, Krong B. Breast cancer in the global south and the limitations of a biomedical framing: a critical review of the literature. Health Policy Plan. 2015. [Epub ahead of print].
3. Mittra I. Breast cancer screening in developing countries. Prev Med. 2001;53:121-2.
4. Zhou X, Wang X, Huang Z, Xu L, Zhu W, Liu P. An ER-associated miRNA signature predicts prognosis in ER-positive breast cancer. J Exp Clin Cancer Res. 2014;33:94.
5. Madhavan S, Gusev Y, Singh S, Riggins RB. ERRγ target genes are poor prognostic factors in Tamoxifen-treated breast cancer. J Exp Clin Cancer Res. 2015;34:45.
6. Pandiella A, Morís F, Ocaña A, Núñez LE, Montero JC. Antitumoral activity of the mithralog EC-8042 in triple negative breast cancer linked to cell cycle arrest in G2. Oncotarget. 2015. [Epub ahead of print]
7. Karami F, Mohammadi-Yeganeh S, Abedi N, Koochaki A, Kia V, Paryan M. Bioinformatics prediction and in vitro analysis revealed that miR-17 targets Cyclin D1 mRNA in Triple NegativeBreast Cancer cells. Chem Biol Drug Des. 2015. doi: 10.1111/cbdd.12671. [Epub ahead of print]
8. Bastian A, Thorpe JE, Disch BC, Bailey-Downs LC, Gangjee A, Devambatla RK, et al. A small molecule with anticancer and antimetastatic activities induces rapid mitochondrial associated necrosis in breast cancer. J Pharmacol Exp Ther. 2015;353:392-404.
9. de Lartigue J. Moving beyond the one-size-fits-all formula for breast cancer treatments. J Community Support Oncol. 2014;12:301-7.
10. Shen Y, Du Y, Zhang Y, Pan Y. Synergistic effects of combined treatment with simvastatin and exemestane on MCF-7 human breast cancer cells. Mol Med Rep. 2015;12:456-62.
11. Palma G, Frasci G, Chirico A, Esposito E, Siani C, Saturnino C, et al. Triple negative breast cancer: looking for the missing link between biology and treatments. Oncotarget. 2015;6:26560-74.
12. Mukherjee AK, Basu S, Sarkar N, Ghosh AC. Advances in cancer therapy with plant based natural products. Curr Med Chem. 2001;8:1467-86.
13. Wang S, Penchala S, Prabhu S, Wang J, Huang Y. Molecular basis of traditional Chinese medicine in cancer chemoprevention. Curr Drug Discov Technol. 2010;7:67-75.
14. Nabavi SM, Habtemariam S, Daglia M, Nabavi SF. Apigenin and breast cancers: from chemistry to medicine. Anticancer Agents Med Chem. 2015;15:728-35.
15. Lee JC, Won SJ, Chao CL, Wu FL, Liu HS, Ling P, et al. Morusin induces apoptosis and suppresses NF-kappaB activity in human colorectal cancer HT-29 cells. Biochem Biophys Res Commun. 2008;372:236-42.
16. Wan LZ, Ma B, Zhang YQ. Preparation of morusin from Ramulus mori and its effects on mice with transplanted H22 hepatocarcinoma. Biofactors. 2014;40:636-45.
17. Lim SL, Park SY, Kang S, Park D, Kim SH, Um JY, et al. Morusin induces cell death through inactivating STAT3 signaling in prostate cancer cells. Am J Cancer Res. 2014;25:289-99.
18. Dat NT, Binh PT, le Quynh TP, Van Minh C, Huong HT, Lee JJ. Cytotoxic prenylated flavonoids from Morus alba. Fitoterapia. 2010;81:1224-7.
19. Lin WL, Lai DY, Lee YJ, Chen NF, Tseng TH. Antitumor progression potential of morusin suppressing STAT3 and NFκB in human hepatoma SK-Hep1 cells. Toxicol Lett. 2015;232:490-8.
20. Lee HJ, da Lyu H, Koo U, Nam KW, Hong SS, Kim KO, et al. Protection of prenylated flavonoids from Mori Cortex Radicis (Moraceae) against nitric oxide-induced cell death in neuroblastoma SH-SY5Y cells. Arch Pharm Res. 2012;35:163-70.
21. Wang L, Guo H, Yang L, Dong L, Lin C, Zhang J, et al. Morusin inhibits human cervical cancer stem cell growth and migration through attenuation of NF-κB activity and apoptosis induction. Mol Cell Biochem. 2013;379:7-18.
22. Guo H, Liu C, Yang L, Dong L, Wang L, Wang Q, et al. Morusin inhibits glioblastoma stem cell growth in vitro and in vivo through stemness attenuation, adipocyte transdifferentiation, and apoptosis induction. Mol Carcinog. 2014. doi: 10.1002/mc.22260. [Epub ahead of print]
23. van Meerloo J, Kaspers GJ, Cloos J. Cell sensitivity assays: the MTT assay. Methods Mol Biol. 2011;731:237-45.
24. Ebrahim K, Shirazi FH, Vatanpour H, Zare A, Kobarfard F, Rabiei H. Anticancer activity of Cobra Venom polypeptide, cytotoxin-II, against human breast adenocarcinoma cell line (MCF-7) via the induction of apoptosis. J Breast Cancer. 2014;17:314-22.
25. Zhang H, Xu HL, Fu WW, Xin Y, Li MW, Wang SJ, et al. 20(S)-Protopanaxadiol induces human breast cancer MCF-7 apoptosis through a caspase-mediated pathway. Asian Pac J Cancer Prev. 2014;15:7919-23.
26. Tsai CH, Lin FM, Yang YC, Lee MT, Cha TL, Wu GJ, et al. Herbal extract of Wedelia chinensis attenuates androgen receptor activity and orthotopic growth of prostate cancer in nude mice. Clin Cancer Res. 2009;15:5435-44.
27. Münster PN, Srethapakdi M, Moasser MM, Rosen N. Inhibition of heat shock protein 90 function by ansamycins causes the morphological and functional differentiation of breast cancer cells. Cancer Res. 2001;61:2945-52.
28. Doherty MK, Morris PG. Eribulin for the treatment of metastatic breast cancer: an update on its safety and efficacy. Int J Womens Health. 2015;7:47-58.
29. Sak K. Cytotoxicity of dietary flavonoids on different human cancer types. Pharmacogn Rev. 2014;8:122-46.
30. Yeap S, Akhtar MN, Lim KL, Abu N, Ho WY, Zareen S, et al. Synthesis of an anthraquinone derivative (DHAQC) and its effect on induction of G2/M arrest and apoptosis in breast cancer MCF-7 cell line. Drug Des Devel Ther. 2015;9:983-92.
31. Wang L, Peng Y, Shi K, Wang H, Lu J, Li Y, et al. Osthole inhibits proliferation of human breast cancer cells by inducing cell cycle arrest and apoptosis. J Biomed Res. 2015;29:132-8.
32. Tengku Din TA, Seeni A, Khairi WN, Shamsuddin S, Jaafar H. Effects of rapamycin on cell apoptosis in mcf-7 human breast cancer cells. Asian Pac J Cancer Prev. 2014;15:10659-63.
33. Baharara J, Namvar F, Ramezani T, Mousavi M, Mohamad R. Silver Nanoparticles Biosynthesized Using Achillea biebersteinii Flower Extract: Apoptosis Induction in MCF-7 Cells via Caspase Activation and Regulation of Bax and Bcl-2 Gene Expression. Molecules. 2015;20:2693-706.
34. Minamino M, Oka T, Kanouchi H. Growth suppression and cell death by pyridoxal is dependent on p53 in the human breast cancer cell line MCF-7. Biosci Biotechnol Biochem. 2015;79:124-9.
35. Chiu CC, Haung JW, Chang FR, Huang KJ, Huang HM, Huang HW, et al. Golden berry-derived 4β-hydroxywithanolide E for selectively killing oral cancer cells by generating ROS, DNA damage, and apoptotic pathways. PLoS ONE. 2013;8:e64739.
36. Yan J, Luo D, Luo Y, Gao X, Zhang G. Induction of G1 arrest and differentiation in MDA-MB-231 breast cancer cell by boehmeriasin A, a novel compound from plant. Int J Gynecol Cancer. 2006;16:165-70.
37. Demetri GD, Fletcher CD, Mueller E, Sarraf P, Naujoks R, Campbell N, et al. Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci U S A. 1999;96:3951-6.
38. MacDougald OA, Lane MD. Transcriptional regulation of gene expression during adipocyte differentiation. Annu Rev Biochem. 1995;64:345-73.
39. Thompson WR, Guilluy C, Xie Z, Sen B, Brobst KE, Yen SS, et al. Mechanically activated Fyn utilizes mTORC2 to regulate RhoA and adipogenesis in mesenchymal stem cells. Stem Cells. 2013;31:2528-37.
40. Hu W, Lee SK, Jung MJ, Heo SI, Hur JH, Wang MH. Induction of cell cycle arrest and apoptosis by the ethyl acetate fraction of Kalopanax pictus leaves in human colon cancer cells. Bioresour Technol. 2010;101:9366-72.
41. Sun B, Geng S, Huang X, Zhu J, Liu S, Zhang Y, et al. Coleusin factor exerts cytotoxic activity by inducing G0/G1 cell cycle arrest and apoptosis in human gastric cancer BGC-823 cells. Cancer Lett. 2011;301:95-105.
42. Guo L, Li X, Tang QQ. Transcriptional regulation of adipocyte differentiation: a central role for CCAAT/enhancer-binding protein (C/EBP) β. J Biol Chem. 2015;290:755-61.
43. Zahnow CA. CCAAT/enhancer binding proteins in normal mammary development and breast cancer. Breast Cancer Res. 2002;4:113-21.
44. Kurzejamska E, Johansson J, Jirström K, Prakash V, Ananthaseshan S, Boon L, et al. C/EBPβ expression is an independent predictor of overall survival in breast cancer patients by MHCII/CD4-dependent mechanism of metastasis formation. Oncogenesis. 2014;3:e125.
45. Johansson J, Berg T, Kurzejamska E, Pang MF, Tabor V, Jansson M, et al. MiR-155-mediated loss of C/EBPβ shifts the TGF-β response from growth inhibition to epithelial-mesenchymal transition, invasion and metastasis in breast cancer. Oncogene. 2013;32:5614-24.
46. Costa V, Foti D, Paonessa F, Chiefari E, Palaia L, Brunetti G, et al. The insulin receptor: a new anticancer target for peroxisome proliferator-activated receptor-gamma(PPARgamma) and thiazolidinedione-PPARgamma agonists. Endocr Relat Cancer. 2008;15:325-35.
47. Zheng ZH, Yang Y, Lu XH, Zhang H, Shui XX, Liu C, et al. Mycophenolic acid induces adipocyte-like differentiation and reversal of malignancy of breast cancer cells partly through PPARγ. Eur J Pharmacol. 2011;658:1-8.
48. Chang TH, Szabo E. Induction of differentiation and apoptosis by ligands of peroxisome proliferator-activated receptor gamma in non-small cell lung cancer. Cancer Res. 2000;50:1129-38.
49. Clay CE, Namen AM, Atsumi G, Willingham MC, High KP, Kute TE, et al. Influence of J series prostaglandins on apoptosis and tumorigenesis of breast cancer cells. Carcinogenesis. 1999;20:1905-11.
50. Martinasso G, Oraldi M, Trombetta A, Maggiora M, Bertetto O, Canuto RA, et al. Involvement of PPARs in cell proliferation and apoptosis in human colon cancer specimens and in normal and cancer cell lines. PPAR Res. 2007;2007:93416.
51. Tsubouchi Y, Sano H, Kawahito Y, Mukai S, Yamada R, Kohno M, Inoue K, et al. (2000) Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-gamma agonists through induction of apoptosis. Biochem Biophys Res Commun. 2000;270:400-5.
52. Pohle T, Brändlein S, Ruoff N, Müller-Hermelink HK, Vollmers HP. Lipoptosis: tumor-specific cell death by antibody-induced intracellular lipid accumulation. Cancer Res. 2004;64:3900-6.
53. Schaffer JE. Lipotoxicity: when tissues overeat. Curr Opin Lipidol. 2003;14:281-7.
54. Zhang Z, Zhou Y, Qian H, Shao G, Lu X, Chen Q, et al. Stemness and inducing differentiation of small cell lung cancer NCI-H446 cells. Cell Death Dis. 2013;4:e633.